Metall Zug stock
METN.SWSIXMetall Zug AG, HealthcareISIN CH0039821084
40Score 40 out of 100, Weak
Price and trend
83 / 100
Price history
+14% in one yearThe chart shows daily closes over 20 years, adjusted for stock splits and without dividends. Click into the chart to set a price alert at that price.
Above the 200-day line: the price is 9.4% above it.
Since August 2026 the 50-day line has been above the 200-day line; the trend has turned up.
Normal: the price is neither overheated nor sold off (RSI 61).
The price is 3.2% below its 52-week high. Largest decline in 20 years: 78% (June 2017 to May 2026).
Chart figures for advanced users
- SMA 50$1,024.90
- Average price of the last 50 trading days, shows the short-term trend.
- SMA 200$938.94
- Average price of the last 200 trading days, shows the long-term trend.
- RSI (14)61
- Relative strength over the last 14 days on a scale from 0 to 100. Above 70 the price counts as overheated, below 30 as sharply fallen.
- MACDabove the signal line
- Compares a fast and a slow price average. Above its signal line momentum is rising, below it momentum is fading.
- Support$836.60
- The lowest closing price of the last twelve months.
- Resistance$1,061.05
- The highest closing price of the last twelve months.
Snapshot
Computed from the data by fixed rules, no AI
- Metall Zug AG belongs to the Medical (Devices) industry (Switzerland) and, with a market value of $460.29M, is number 81 of 88 companies in its industry on MEQIRI.
- In fiscal 2025 it reported revenue of $233.6M (down 31.3% year on year) and a loss of $18.29M.
- MEQIRI Score 40 out of 100 (Weak): rank 537 of 702 in Healthcare, median 53.
Show more
- Our model puts fair value at $413.79, with the price 148% above it.
In plain words
The numbers on this page in plain words, written by an AI
Strengths
None of our strength checks applies.
Weaknesses
- Above fair valuePrice 148% above the fair value of $413.79.Valuation 5
- Revenue shrinkingRevenue down 25.1% a year since 2020.Growth 5
- Loss-makingLoss of $12.97M over the last 12 months.Fundamentals 46
Its standout strengths are technical analysis and momentum, while growth and valuation hold the score back.
Daily figure as of 13 Nov 2026
How the score is calculatedScore overview
Score since yesterday from 38 to 40.
Fundamental quality fluctuates.
Score history
The full history of up to 20 years comes with MEQIRI Pro.
See plansCrash risk low
How well MEQIRI warnsOne of the 30% with the lowest crash risk among smaller stocks.
From 2016 to 2025, 14 in 100 such stocks fell 30% or more within a year, against a group average of 23 in 100.
What drives the risk
- weak fundamentals
What lowers it
- low growth grade (crashed less often in the backtest)
- calm price action
- price near its 52-week high
Valuation
Valuation signal
Significantly overvaluedIn our model the price counts as cheap below $344.83 and expensive above $517.24 (uncertainty low, based on the price swings of the past year).
Calculated with a cost of equity of 6.4%. At 7.4% the fair value would be $353.21, at 5.4% it would be $499.47.
Valuation metrics
From the dividend model alone; without earnings there is no industry value.
Calculate with your own assumptionsCompany performance
This shows several years of history with an automatic assessment.
Revenue
In the twelve months to 30 Jun 2026, revenue fell 0.3% on the twelve months before. Revenue has declined since 2006 (-5% per year), so it is worth watching closely.
Margins
- Gross margin
- Operating margin
- Net margin
In fiscal 2025: gross 32%, operating −14%, net −8%.
Debt & balance sheet
latest quarterDebt is moderate, but interest coverage is weak. Keep an eye on the interest burden and refinancing.
Earnings
- Next earnings
- 22 Mar 2027in 129 days
- Last reported
- 24 Aug 2026EPS reported −$14.39
Analyst estimates
Earnings estimates have barely changed since 15 Oct 2026.
- Earnings per share
- $7.200.0%
- Revenue
- $241.24M0.0%
- Earnings per share
- $30.130.0%
- Revenue
- $265.37M0.0%
MEQIRI has stored the estimates since 15 Oct 2026. Until 30 days are available, the card shows the change since that day. Mean estimate according to Financial Modeling Prep. No price target and no recommendation.
What happened at Metall Zug
The key events of the last six months from our own data. A click takes you to the matching card.
Sector comparison
702 rated companies in Healthcare
- This company
- 40
- Sector median
- 53
Categories against the sector median
The median is the middle value: half of the companies in the sector lie above it, half below. Categories with too few comparable companies are left out.
Competitors in Medical (Devices)
The next larger and next smaller companies by market value
- Anteris Technologies GlobalAVR $571.11M33
- Ion Beam ApplicationsIBAB.BR $555.09M58
- Avita MedicalRCEL $500.03M47
- CellaVisionCEVI.ST $483.11M80
- Revenio GroupREG1V.HE $419.17M47
- NeuroPaceNPCE $412.58M32
- ImplanticaIMP-A-SDB.ST $400.4M50
- CerusCERS $391.79M33
Data status and sources
- Score
- Daily value of 13 Nov 2026, recalculated nightly
- Price
- Closing price of 12 Nov 2026
- Latest annual report
- Fiscal year 2025, period end 31 Dec 2025
- Currency
- Amounts in US dollars, converted at the ECB reference rate of 12 Nov 2026 ($1 = CHF 0.8331)
- Source
- Financial statements, ratios and prices from Financial Modeling Prep (FMP), based on the company's reports. MEQIRI calculates the score and fair value from them.
Mandatory disclosures for this rating
- ; time horizon around 12 months
- Rated Weak, published since 7 Nov 2026 (in the score history since 29 Aug 2025)
- Valuation signal Overvalued since 7 Nov 2026
- End-of-day prices, metrics cached for up to 24 hours
- Score and fair value are estimates from a disclosed model. They are not facts and not a price target.
- Produced by SSM Ventures UG (haftungsbeschränkt), responsible person Sven Brostmeyer, Managing Director, automatically according to the disclosed model.
- Not investment advice. Losses up to and including a total loss are possible. Personal circumstances are not considered.